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The retroviral proteinase (PR) seems to play crucial
roles in the viral life cycle, therefore it is an attractive
target for chemotherapy. Previously we studied the
specificity of human immunodeficiency virus (HIV) type
1 and type 2 as well as equine infectious anemia virus
PRs using oligopeptide substrates. Here a similar ap-
proach is used to characterize the specificity of avian
myeloblastosis virus (AMV) PR and to compare it with
those of the previously characterized lentiviral PRs. All
peptides representing naturally occurring Gag and Gag-
Pol cleavage sites were substrates of the AMV PR. Only
half of these peptides were substrates of HIV-1 PR. The
Km values for AMV PR were in a micromolar range pre-
viously found for the lentiviral PRs; however, the kcat
values were in a 10–30-fold lower range. A series of pep-
tides containing single amino acid substitutions in a
sequence representing a naturally occurring HIV cleav-
age site was used to characterize the seven substrate
binding subsites of the AMV PR. The largest differences
were found at the P4 and P2 positions of the substrate.
Detailed analysis of the results by molecular modeling
and comparison with previously reported data revealed
the common characteristics of the specificity of the ret-
roviral PRs as well as its strong dependence on the
sequence context of the substrate.
Due to its crucial role in the early phase (1–3) as well as in
the late phase of viral life cycle (for review see Ref. 4), retroviral
proteinase (PR)1 is a promising target for drug intervention;
potent inhibitors developed to block its action are now in ad-
vanced clinical trials (5). However, as in the case of reverse
transcriptase inhibitors, resistance rapidly develops, both in
vitro and in vivo (6). Studies to determine the common features
of the specificity of different retroviral PRs may help to design
broad spectrum inhibitors and reduce the possibility of viable
mutants. Therefore, we have extensively studied the specificity
of HIV-1,2 HIV-2 (7–9), EIAV (10, 11), and bovine leukemia
virus (12) PRs using oligopeptide substrates representing the
naturally occurring cleavage sites, as well as a peptide series
containing single amino acid substitutions in the P4-P393 posi-
tions of the cleavage site sequence between the matrix (MA)
and capsid (CA) proteins of HIV-1. This MA/CA cleavage site
sequence has Tyr2Pro at the site of the cleavage (the down
arrow indicates the cleavable peptide bond). Recent analysis of
retroviral cleavage site sequences (13) and kinetic studies on
HIV PRs (9, 14) suggest that two major types of cleavage sites
exist for retroviral proteinases: one having Tyr2Pro (type I)
and the other having mainly hydrophobic residues but not Pro
(type II) at the site of cleavage.
The avian type C viruses code the PR on the gag gene;
therefore, unlike the other retroviruses, PR is made in equiv-
alent amounts to the structural proteins and was relatively
easy to purify. Many of the early studies on the role and
specificity of retroviral PR used AMV/RSV4 as a model system
(for review see Ref. 15). RSV PR was the first retroviral enzyme
for which the crystal structure was determined (16). Subse-
quently, many crystal structures have been determined of
HIV-1 and HIV-2 PRs in the absence and the presence of
inhibitors (17). AMV/RSV PR is still in focus of intensive spec-
ificity and mutagenesis studies (18–22). Some RSV cleavage
site peptides have been previously studied as substrates of the
retroviral enzymes (20, 23). Here we report the comparison of
the AMV and HIV-1 proteinases based on a complete set of
substrates representing naturally occurring cleavage sites. Re-
cently Cameron et al. (21) used a series of substrates containing
single amino acid substitutions in the type II NC/PR cleavage
site sequence of RSV to compare the specificity of RSV and
HIV-1 PRs. Here, we compare the specificity of AMV and HIV-1
PRs using a series of peptides containing single amino acid
substitutions in the type I MA/CA sequence of HIV-1. Detailed
analysis of the results by molecular modeling and comparison
with previously published data on retroviral proteinases has
revealed the common characteristics of the specificity of retro-
viral PRs as well as its strong dependence on the sequence
context of the substrate.
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MATERIALS AND METHODS
Retroviral Proteinases
AMV PR purified from virus as described (24), was obtained from
Molecular Genetic Resources (Tampa, FL). Recombinant purified HIV-1
PR (25) used for the peptides representing naturally occurring cleavage
sites in RSV was a kind gift of Dr. Y. S. E. Cheng (Experimental Station,
The DuPont Merck Pharmaceutical Company, Wilmington, DE). Active
site titration of the enzymes was performed using Pro-Pro-Cys-Val-
PheSta-Ala-Met-Thr-Met for AMV PR (23) and a phosphinic acid-type
substrate based inhibitor (compound 3 in Ref. 26) for HIV-1 PR.
Oligopeptides
Oligopeptides were synthesized by standard tert-butoxycarbonyl or
9-fluorenylmethyloxycarbonyl chemistry on a model 430A automated
peptide synthesizer (Applied Biosystems, Inc.) or a semiautomatic Vega
peptide synthesizer (Vega-Fox Biochemicals). Some peptides were syn-
thesized by fragment condensation as described previously (27). Amino
acid composition of the peptides was determined with either a Durrum
D-500 or a Waters Pico-Tag amino acid analyzer. Stock solutions and
dilutions were made in distilled water (or in 10 mM dithiothreitol for
peptides containing Cys residues), and the peptide concentrations were
determined by amino acid analysis.
Enzyme Assay
The assays for the kinetic measurements were performed in 0.25 M
phosphate buffer, pH 5.6, containing 5% glycerol (7.5% glycerol for
HIV-1 PR), 5 mM dithiothreitol, 1 mM EDTA, and 2 M NaCl as described
previously (7–9). The reaction mixture was incubated at 37 °C for 1 h
and was stopped by the addition of 9 volumes of 1% trifluoroacetic acid
and then injected onto a Nova-Pak C18 reversed-phase chromatography
column (3.9 3 150 mm, Waters Associates, Inc.) using an automatic
injector. Substrates and the cleavage products were separated using
acetonitrile gradient (0–100%) in water in the presence of 0.05% tri-
fluoroacetic acid. The cleavage of peptides was monitored at 206 nm,
and the peak areas were integrated. Amino acid analysis and/or N-
terminal sequencing of the collected peaks was used to confirm the
cleavage sites in the substrates. N-terminal sequencing was performed
using a KNAUER Model 910 protein sequencer. The substrate concen-
trations used for the kinetic measurements were in the range of 0.01–3
mM, depending on the approximate Km values. Kinetic parameters were
determined at less than 20% substrate turnover by fitting the data to
the Michaelis-Menten equation using the Gauss-Newton method using
Fig.P program (Fig.P Software Corp., Durham, NC). The standard
errors of the kinetic parameters were below 20%. Substrate hydrolysis
followed Michaelis-Menten kinetics in the concentration range of sub-
strates used. For the determination of relative activities, the reaction
mixture containing 0.4 mM peptide was incubated at 37 °C for 1 or 24 h
as described previously (11, 12). Amino acid analysis of the collected
peaks was used to confirm the site of cleavage with HIV PR (9, 12). For
the AMV PR, cleavage products were identified by the retention time,
which was found to be identical to that obtained with HIV PR. Relative
activities were calculated from the molar amounts of peptides cleaved
per unit time by dividing the activity on a given peptide by the activity
on the unmodified substrate SP-211 (Val-Ser-Gln-Asn-Tyr2Pro-Ile-
Val-Gln), at less than 20% substrate turnover, as described in Bla´ha et
al. (12). Measurements were performed in duplicate, and the average
values were calculated. The error was less than 20%. The relative
activities for the HIV-1 PR have been reported previously (11).
Methods for Modeling Calculations
Initial Model—The crystal structures of the native RSV PR with a
modeled flap and peptide substrate (20) and HIV-1 PR complexed with
a modeled substrate Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln (9) were super-
imposed using Ca atoms and examined on a Silicon Graphics 310
computer graphics system runnung the program CHAIN (28) or a
Silicon Graphics Indigo computer graphics system using the program
Sybyl (Tripos Inc., St. Louis, MO). The residues forming the subsites for
Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln were determined previously for HIV-1
and HIV-2 PR (8, 9), and the corresponding residues in AMV/RSV PR
were obtained from the structural alignment. Models of the series of
peptide variations of Pro-Ala-Val-Ser-Leu-Ala-Met-Thr that represent
the NC/PR cleavage site of RSV are described separately.5 The protein-
ase substrate complexes were modeled with a proton positioned midway
between the closest side chain oxygens of the two adjacent catalytic
aspartates, Asp-25 and Asp-259, and the carbonyl oxygen of the scissile
bond. The position of this proton has been shown to be energetically
stable by molecular dynamics simulations (29). All the crystallographic
water molecules were included because several appeared to be struc-
turally important.
Energy Minimization Calculation—The minimization and molecular
dynamics were run using the program AMMP (30). No screening dielec-
tric term or bulk solvent correction was included. A constant dielectric
of one was used. No cut-off was applied for nonbonded and electrostatic
terms, as described in Harrison and Weber (29). A modified version of
the UFF potential set (31) was used as described separately.5 These
modifications do not significantly change the performance of the poten-
tial set on small molecules but result in constantly smaller root mean
square deviations between minimized and observed protein structures.
The atomic charges from the AMBER all-atom set were used for the
protein and water (32). Parameters for water and for the proton were as
described (29). The atomic positions for the protein and water molecules
were initially tethered to those in the crystal structure of AMV PR in
order to calculate and minimize the hydrogen atom positions. The side
chain atoms of the substrate peptide were removed down to the Cb atom
for the substituted amino acids, and the new atomic positions were
created by a variation on distance geometry (33). The new atoms were
minimized with respect to bond, angle, torsion, and hybrid potentials.
The proteinase structure with nonhydrogen atoms from the crystal
structure and minimized hydrogen atoms was combined with each of
the different peptides with single amino acid substitutions. Then each
of the side chain torsion angles for substituted residues in the peptide
substrate was rotated through 360 ° in steps of 15 ° to search for
alternate conformations. This torsion search finds the angle(s) that
have a minimum in the nonbonded energy. The substrate atoms were
minimized using 300 steps of conjugate gradients. Finally, the complete
model of AMV PR with each different substrate was optimized by a
longer minimization using 100 steps of conjugate gradients followed by
eight cycles of alternating conjugate gradients (30 steps) and short runs
of molecular dynamics (20 fs steps at 300 K).
RESULTS AND DISCUSSION
Hydrolysis of Oligopeptides Representing Naturally
Occurring Cleavage Sites
Ten oligopeptides representing naturally occurring cleavage
sites in the RSV Gag and Gag-Pol polyproteins (Fig. 1) were
tested as substrates for AMV and HIV-1 PRs (Table I). All
peptides were hydrolyzed at the expected site by the AMV
enzyme, except peptide 10, which was hydrolyzed at the
Gly2Ile bond instead of the Ala2Gly bond, the site in RSV IN
reported by Grandgenett et al. (34). For this peptide, the same
site of cleavage was also observed at low ionic strength, in the
absence of additional salt (data not shown). The RSV IN pro-
tein is phosphorylated at the Ser residue near the cleavage site
in the C terminus (P6 position of peptide 10 in Table I; see Ref.
35). It should be noted that phosphorylation was found to alter
the C-terminal processing of IN. It would be interesting to
determine whether phosphorylation of the serine would cause a
shift in the cleavage site. Kinetic parameters were determined
at high (2 M) salt concentration. High ionic strength was found
to be optimal for AMV PR (36), similar to other retroviral PRs
(10, 37, 38). The range of kinetic parameters was compared
with that we previously determined for the lentiviral PRs using
peptides representing cleavage sites in their Gag and Gag-Pol
polyproteins (Table II). The Km was found to be also in the
micromolar range, although one peptide showed an exception-
ally high value (peptide 9 in Table I). However, the kcat values5 I. T. Weber and R. W. Harrison, submitted for publication.
FIG. 1. Cleavage sites in RSV Gag and Gag-Pol polyproteins.
Cleavage sites were determined by sequencing purified virion proteins
(reviewed in Ref. 15). The frameshift site is marked by an asterisk.
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were in a 10–30-fold lower range than those of other PRs (Table
II). This is in good agreement with the relative amounts of the
PR in the virions. Although the PR of the HIVs and EIAV is
coded for by the pol gene and is synthesized in an approxi-
mately 10–20-fold lower amount than the Gag proteins, the PR
of AMV is encoded in the gag gene (Fig. 1), and therefore it is
synthesized equimolarly to the structural Gag proteins.
The peptides were also assayed as substrates of HIV-1 PR.
Only half of them were substrates of this enzyme with similar
kinetics to that obtained with the AMV PR except for peptide 6,
which was the best substrate of both enzymes, with kinetic
parameters comparable with the best values obtained for pep-
tides representing the HIV naturally occurring cleavage sites
(Table II).
By comparing the amino acids at the P1-P19 region of the
cleavage sites, it is obvious that the three lentiviral PRs prefer
hydrophobic residues (7, 10), whereas AMV PR seems to toler-
ate glycine or polar residues. Nevertheless, the two peptides
with the best kcat/Km values (peptides 4 and 6 in Table I)
contain hydrophobic residues at both P1 and P19 positions.
Mapping of the Substrate Binding Site of AMV with a
Series of Peptides Containing Tyrosine and Proline at the
Cleavage Site
Peptides containing single amino acid substitutions in the
sequence of the cleavage site found between MA and CA of
HIV-1 were assayed as substrates of AMV PR. Kinetic param-
eters for the unmodified peptide (peptide 11 in Table I) suggest
that although it is a poor substrate of AMV PR, it is comparable
with some of the peptides representing naturally occurring
RSV cleavage sites. We have previously determined relative
activites compared with the unmodified peptide of the HIV-1,
HIV-2, and EIAV PRs for the substituted peptides to compare
the specificity of the enzymes (9, 11, 12). Relative activities of
AMV PR are listed in Table III. The kcat/Km values determined
for a set of these substrates (data not shown) correlated well
with the relative activites (r 5 0.987; n 5 15). Residues forming
the substrate binding sites of HIV-1 have been determined
from the crystal structures of HIV-1 PR inhibitor complexes.
Based on homology (Fig. 2) and modeling of the substrate into
the RSV PR, residues predicted to form the respective subsites
compared with the HIV-1 PR are listed in Table IV together
with the respective HIV-1 residues and are shown in Fig. 3. By
analogy to the peptidic inhibitors (17), the substrate is pre-
dicted to bind in an extended b conformation, therefore alter-
native subsites such as S3 and S1 are adjacent to one another
(Fig. 3A). The results from the type I series of peptides based on
the HIV-1 MA/CA cleavage site can be compared with those
using type II peptides based on the RSV NC/PR cleavage site
(21) in order to identify differences due to the sequence context.
Schematic representations of the HIV-1 MA/CA and RSV
NC/PR substrates together with the preferred substitutions are
shown in Fig. 4.
S4 Subsite—The S4 subsite of AMV PR is near the surface of
the proteinase, as observed for other retroviral proteinases. In
this position the side chain of P4 residue may be partially
exposed to solvent. In accordance with this, polar substitutions
(like Lys, Arg, and Asn) of the original Ser in P4 resulted in
fairly good substrates of AMV PR (Table III). However, com-
pared with HIV proteinases, substitution with bulky hydropho-
bic residues gave much higher activity in our series of peptides
(see Table III). The best value was obtained with the Ile sub-
stitution. AMV PR behaves similarly to EIAV PR in preferring
hydrophobic residues at P4 (11). However, with the EIAV en-
zyme, the Leu substitution gave the best result, and the in-
creases in relative activities were much less pronounced. Com-
pared with HIV proteinases, EIAV PR contains extra residues
leading to the tip of the flap that could be involved in S4-P4
interaction, and the S4 pocket is predicted to be more hydro-
phobic than that of HIV PRs (11). Extra residues leading to the
flap are also predicted for AMV PR; modeling of RSV PR
predicted that Pro-62 and Gln-63, derived from the flaps, may
interact with the side chain of P4 (20). These additional amino
TABLE I
Hydrolysis of oligopeptides representing naturally occurring cleavage sites by AMV and HIV-1 proteinases
Place of cleavage Peptide sequence
AMV PR HIV-1 PR
Km kcat kcat/Km Km kcat kcat/Km
mM s21 mM21s21 mM s21 mM21s21
In RSV
1 MA/p2A GTSCY2 HCGTA 0.96 0.062 0.06 0.125 0.31 2.48
2 p2A/p2B GCNCA2 TASAP hydrolyzeda hydrolyzeda
3 p2B/p10 PPYVG2 SGLYP 0.01 0.005 0.50 not hydrolyzedb
4 p10/CA PVVAM2 PVVIK ,0.03 0.04 4.9c not hydrolyzedb
5 CA/p3 IAAAM2 SSAIQ 0.51 0.005 0.01 not hydrolyzedb
6 p3/NC IQPLIM2 AVVNR 0.02 0.19 11.9 0.02 .0.8 318c
7 NC/PR PPAVS2 LAMTM 0.052 0.05 2.5 0.088 0.01 0.13
8 PR9/RT RATVL2 TVALH 0.04 0.04 1.00 ,0.04 .0.04 1.9d
9 RT/IN TFQAY2 PLREA 1.88 0.001 0.015 0.555 0.10 0.18
10 IN/p4 SPLFAG2 ISDWe 0.27 0.001 0.005 not hydrolyzedb
In HIV-1
11 MA/CA VSQNY2 PIVQf 0.38 0.006 0.015 0.15 6.8 45.3
a Cleaved at the expected site, but kinetics was not done. Dithiothreitol peaks covered the product peaks.
b Detection limit: 0.001 nmol product/s/nmol enzyme.
c Determined with a competition assay with peptide 11.
d Determined with a competition assay with peptide 9.
e This peptide is cleaved at Gly 2 Ile bond, whereas the natural cleavage site was found to be between Ala and Gly. Residue corresponding to
the N-terminal Ser has been found to be phosphorylated in the IN protein (35).
f Values for the HIV-1 PR have been published previously (9).
TABLE II
Range of kinetic constants determined for retroviral proteinases
using oligopeptides representing naturally occurring cleavage
sites in their Gag and Gag-Pol polyproteins
Virus Range of Km Range of Kcat Range of kcat/Km
mM s21 mM21s21
HIV-1a 0.006–0.47 0.01–6.8 0.02–202.0
HIV-2a 0.01–0.55 0.3–2.6 1.00–60.0
EIAVb 0.01–0.27 0.01–6.1 0.01–122.0
AMVc 0.01–1.88 0.001–0.19 0.005–11.9
a Taken from To¨zse´r et al. (7).
b To¨zse´r et al. (10) and our unpublished results.
c Taken from Table I.
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acid residues in AMV/RSV PR are predicted to provide a more
enclosed S4 subsite, capable of accommodating hydrophobic
residues. When residues 61–63 were deleted from AMV/RSV
PR, the avian enzyme utilized substrates with polar residues
(Asn or His) in P4, similarly to HIV-1 PR (22). Based on map-
ping RSV PR subsites with a series of peptides based on the
NC/PR cleavage site, the original P4 Pro and its His substi-
tuted analog gave the best result (Fig. 4), whereas substitution
of Leu or Phe resulted in nonhydrolyzable peptides (21). This is
predicted to be due to the presence of b-branched Val in P2
position of the NC/PR peptide, which may restrict the internal
space of S4 for P4 residue, whereas in the MA/CA peptide the
P2 Asn may allow larger hydrophobic residues to be accommo-
dated (Fig. 5). Interestingly, MuLV PR also behaved similarly
to EIAV PR and AMV PR but differently from HIV PRs when
mapped by the same Tyr2Pro peptide series (38). However,
MuLV PR does not seem to have extra residues leading to the
flap but was predicted to have a more hydrophobic pocket due
to extra residues from another part of the molecule.
Subsites S3 and S39—With the P3 substitutions, less dra-
matic results were obtained than with the P4 changes, as was
also found with EIAV and MuLV proteinases (11, 38). The
ability of the S3 subsite to accommodate a variety of residues is
also seen with substitutions in the P3 position of the NC/PR
cleavage site peptide (21). Substitution of Gln to Leu and es-
pecially to Phe in the Tyr2Pro peptide provided substantially
better substrates (Table III and Fig. 4). Interestingly, the
change of P39 Val to Phe gave a dramatic increase in the
relative activity, whereas Leu did not provide any increase over
the original peptide. The S3 subsites of HIV-1 and AMV/RSV
PR consist of relatively open and deep pockets that are near the
surface (21). This could allow side chains of amino acids in the
P3 position freedom of movement to either interact with hydro-
phobic residues near the S1 subsite or polar residues at the
surface of the enzyme (21). In our series, hydrophobic side
chains are greatly preferred over polar residues. In the NC/PR
peptide, the P1 residue is a small Ser, whereas in our series the
large P1 Tyr may restrict the conformations available for the
P3 residue. However, there may be a favorable hydrophobic
interaction of Phe P3 with the P1 Tyr side chain. Interestingly,
Val and Leu substitutions gave very poor substrates for EIAV
PR (11) but fairly good ones for AMV PR.
The most marked changes in the S3 pocket of AMV PR are
Arg-1059 instead of Pro-819 and Gly-1069 instead of Val-829. In
both of these positions EIAV PR contains the same residue as
the HIV-1 PR. The preference for Phe in P3 by AMV/RSV PR
relative to HIV-1 PR can be explained by the presence of
Gly-1069 in AMV/RSV PR, as compared with Val-829 in the
analogous position of HIV-1 PR (21) and Val-879 of EIAV PR.
Val-829 is at the top of the HIV-1 S3 subsite pointing into the
pocket (Fig. 3B) so that it could sterically interfere with the
binding of a large amino acid residue such as Phe. This steric
hindrance is not present with Gly in the AMV/RSV subsite.
The AMV/RSV PR S3 subsite also contains 2 basic residues,
His-65 and Arg-105, not found in the HIV-1 S3 subsite. These
residues confer on portions of the avian subsite a greater de-
gree of hydrophilicity (21). However, the charged groups of
these amino acids are not positioned to provide strong ionic
interactions with substrate as evident from the very poor cat-
alytic efficiency of Asp substituted peptide. The aliphatic side
chain of Arg-105 in AMV/RSV PR may have an important
hydrophobic role in defining the S3 subsite. In agreement with
these results, Konvalinka et al. (39) found that HIV-1 PR will
accept a variety of residues in the P3 position, whereas Strop et
al. (23) reported that the AMV enzyme has a preference for
large polar or nonpolar residues at this position.
Regarding the S39 pocket, the best value was obtained with
Phe substitution, similar to the results obtained with the S3
substituted peptides. Substitution with Arg also gave a sub-
strate better than the original one. The preference for Phe over
the unsubstituted Val was also found for HIV-1 and HIV-2 PRs
(9) and EIAV PR (11). An interesting difference from these
TABLE III
Relative activities obtained with MAV and HIV-1 proteinases for substrates having single amino acid substitutions from position P4 to P39
The numbers in parenthesis were taken from To¨zse’r et al. (10). The relative activities were calculated by determining the molar amount of
peptide cleaved and dividing the activity on a given peptide by the activity obtained with the unmodified substrate Val-Ser-Gln-Asn-Tyr 2
Pro-Ile-Val-Gln-NH2 at 0.4 mM concentration.
Substitutions Ser P4 Gln P3 Asn P2 Tyr P1 ProP19 Ile P29 Val P39
Ala 2.2 (0.3) 0.42 (0.34) 40.7 (0.53) 0.01 (,0.01) 1.8 (0.17)a 0.43 (0.34)
Leu 11.3 (0.02) 2.0 (0.40) 4.3 (0.06) 0.21 (0.21) 0 (0) 0.44 (0.44)a 1.0 (3.2)
Val 9.1 (0.05) 0.50 (0.71) 21.5 (0.17) 0.02 (0) 0 (0) 2.2 (0.93)a
Ile 19.3 (0.03) 12.4 (0.1) 0 (0) 0 (0)
Phe 10.2 (0.03) 2.4 (0.22) 0.25 (0.03) 1.6 (1.7) 0 (0) 0.07 (0.07)a 12.0 (2.4)
Trp 0.02 (0.01) 0 (0)
Gly 0.16 (0.76) 0.03 (0.18) 1.6 (0.12) 0 (0) 0.05 (,0.01)a 0.17 (0.24)
Ser 0 (0) 0 (0) 0.46 (0.36)
Thr 0.82 (0.02) 1.00 (0.40)
Met 5.8 (0.04) 0.17 (0.23)
Asp 0.78 (0.17) 0.01 (,0.01) 0.47 (0.13) 0 (0) 0.01 (,0.01)a 0.13 (0.05)
Asn 1.4 (0.17) 0.05 (0.50) 0.01 (0.01)a
Glu 0.40 (0.1)
Gln 0.01 (0.03) 0.89 (0.67)
Lys 2.9 (0.06) 0.07 (0.12) 0 (0) 0 (0) 0 (0)a 0.27 (0.1)
Arg 0.8 (0.15) 2.70 (0.57)
Cys 35.6 (0.92) ,0.01 (,0.01)
a Taken from Bla´ha et al. (27).
FIG. 2. Sequence of HIV-1 and AMV proteinases. The sequence of
AMV PR differs only at two residues from RSV PR, the latter contains
Thr instead of Ala-52 and Leu instead of Val-82. These residues are not
expected to change the substrate specificity.
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enzymes is that they also prefer Leu in this position while the
AMV PR does not.
Subsites S2 and S29—By changing the P2 Asn of SP-211 to
small or medium sized hydrophobic residues, a substantial
increase in relative activities was obtained, whereas for HIV-1
PR (and also for HIV-2 PR), the original Asn gave the best
results. Strop et al. (23), using AMV PR, also found a preference
for small hydrophobic residues in S2. EIAV PR (11) and MuLV
TABLE IV
Residues forming the subsites of AMV and HIV-1 PRs
Amino acid residues in the second subunit of the dimer are indicated by a prime. The residues that differ in the two PRs are indicated as HIV-1
PR residue/AMV PR residue and are shown in bold. The residues in the extra loop of the AMV PR flap are in parentheses.
Subsite HIV-1/AMV residues
S4 Asp 29/41, Asp 30/Ile 42, (Pro 62, Gln 63), Ile 47/64, Val 56/Met 73, Leu 76/Ala 100
S3 Arg 89/109, Leu 239/359, Asp 29/41, Gly 48/His 65, Gly 49/66, Phe 53/Gly 70, Pro 81*/Arg 105*, Val 82*/Gly 106*
S2 Ala 28/40, Asp 29/41, Asp/Ile 42, Val 32/Ile 44, Ile 47/64, Gly 48/His 65, Gly 49/66, Ile 509/679, Val 56/Met 73, Leu
76/Ala 100, Ile 84/108
S1 Arg 89/109, Leu 239/359, Asp 259/379, Asp 25/37, Gly 27/39, Gly 49/66, Ile 50/67, Thr 80*/Val 104*, Pro 81*/Arg 105*, Val
82*/Gly 106*, Ile 849/1089
S19 Arg 8/10, Leu 23/35, Asp 25/37, Asp 259/379, Gly 279/399, Gly 499/669, Ile 509/679, Thr 80/Val 104, Pro 81/Arg 105, Val
82/Gly 106, Ile 84/108
S29 Ala 289/409, Asp 299/419, Asp 30*/Ile 42*, Val 32*/Ile 44*, Ile 479/649, Gly 48*/His 65*, Gly 499/669, Ile 50/67, Val 56/Met
73, Leu 76*/Ala 100*, Ile 849/1089
S39 Arg 8/10, Leu 23/35, Asp 299/419, Gly 48*/His 65*, Gly 499/669, Phe 53*/Gly 70*, Pro 81/Arg 105, Val 82/Gly 106
FIG. 3. A, schematic representation of
the HIV-1 MA/CA substrate in the S4-S39
subsites of PR. The relative size of each
subsite is indicated approximately by the
area enclosed by the curved line around
each substrate side chain. Proteinase res-
idues forming the subsites are shown for
those that differ between the AMV and
HIV-1 PRs. The HIV-1 PR residues are in
parentheses. Many of the residues con-
tribute to more than one subsite, as indi-
cated by the position of the label. B, ste-
reoview of residues P4-P1 of the HIV-1
MA/CA cleavage site with the substrate-
binding residues that differ in AMV and
HIV-1 PRs. The same residues are shown
as indicated in the scheme of A and Table
IV. The AMV PR residues (thin continu-
ous lines) are from the crystal structure of
RSV protease (16). The HIV-1 PR resi-
dues (dashed lines) and the substrate res-
idues (thick lines in a ball-and-stick rep-
resentation) are from a model based on
the crystal structures of HIV protease
with peptide-like inhibitors. The model-
ing procedure is described under “Materi-
als and Methods.”
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PR (38) also preferred medium sized hydrophobic residues at
this position, although the increases in relative activities or
kcat/Km values were much less pronounced (maximum 10-fold
increase) than observed for AMV PR. There is a difference in
the preferred size of the hydrophobic side chains. For AMV and
EIAV PR the smaller Ala, Cys, and Val gave the best results
(Table III., Ref. 11), whereas MuLV PR preferred the bulkier
aliphatic Leu and Ile (38). However, it seems to be a common
result that Phe at P2 forms a poor substrate; modeling suggests
that the Phe side chain is too bulky for this subsite. Therefore,
in the type I sequence context, the preference for Asn by the
HIV PRs is rather exceptional, because the other studied ret-
roviral proteinases showed much higher preference for small or
medium sized hydrophobic residues.
The S2 subsites of all PRs are sterically more restricted
compared with the S4 and S3 subsites and are predicted to
accommodate hydrophobic residues. The P2 side chain is sur-
rounded by five Ile side chains in AMV PR (residues 42, 44, 64,
108, and 679), and three of them are conserved in HIV-1 PR, but
the residue corresponding Ile-44 is Val-32, and that corre-
sponding to Ile-42 is Asp-30. The ability of HIV-1 PR to accom-
modate more polar residues may be related to the presence of
Asp-30 (21). In analogous positions, the Thr in EIAV (11) and
His in MuLV (38) also may be responsible for accommodation of
more polar P2 residues. The two residues that seem to be
crucial in determining the preference for Val over Leu at P2 in
our substrate series are Ile-44 and Ile-64. The corresponding
side chains of retroviral proteinases are shown in Table V.
Based on this comparison, in both positions Ile favors Val at P2
in the substrate, whereas Val favors Leu. However, in this
respect the residue equivalent to Ile-64 seems to be more cru-
cial in the comparison of HIV-1 and HIV-2 values. A Val pref-
erence over Leu was obtained for wild type AMV/RSV PR, but
a Leu over Val preference for HIV-1 PR using a substrate series
based on the NC/PR cleavage site and predicted to be due to the
role of Ile-44 compared with Val-32 in HIV-1 PR (21). A mutant
RSV PR containing Val in place of this Ile resulted in higher
relative activity than the wild type enzyme for the Leu substi-
tuted peptide, but the preference for Val still remained (22).
The removal of a methyl group in the side chain of the sub-
strate can be compensated for by the addition of a methyl group
to the side chain of the amino acid in the enzyme subsite, as
suggested by Cameron et al. (21); optimization of van der
Waals’ interactions in the individual enzyme subsites is a pri-
FIG. 4. Schematic representation of the HIV-1 MA/CA (A) and
RSV NC/PR (B) substrates. Preferred substitutions for the HIV-1
peptide by the AMV PR (based on Table III) and those for the RSV
substrate by AMV PR (based on Ref. 21) are listed under the residues.
FIG. 5. Interactions of P4 and P2 residues. Residues forming the S4 to S2 subsites of RSV (thin continuous lines) and HIV-1 (dashed lines)
proteinases are shown together with P3-P1 residues of two different substrates (in a ball-and-stick representation). The MA/CA substrate of HIV-1
with Leu at P4 is shown in thicker lines, and the NC/PR substrate of RSV with Leu at P4 is in thinner lines. The HIV-1 PR residues and the
substrate residues are from models based on the cystal structures of HIV-1 PR with peptide-like inhibitors.
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mary determinant in selection of amino acids in the different
substrate positions.
The S29 subsite, like S2, is also predicted to accommodate
smaller hydrophobic residues. In accordance with this, the best
result was obtained with Ala substitution. It is interesting to
note that the changes in relative activities are not as marked
than as for the P2 substitutions, the Ile residue of the unmod-
ified peptide could already provide good interactions. This also
seems to be common with EIAV PR and MuLV PR using the
same substrate series (11, 38) and for HIV-1 and RSV PR using
the NC/PR based series (21) in which Ala at P29 gave the best
result (21). For AMV PR, Strop et al. (23) reported an appar-
ently symmetrical requirement for small hydrophobic residues
in both P2 and P29 and large hydrophobic residues in P1 and
P19. However, their series was based on a type II cleavage site
containing two hydrophobic residues at both P1 and P19 posi-
tions (Tyr and p-nitophenyl residues, respectively), whereas
our series was based on a type I (Tyr2Pro) cleavage site
peptide. Studying HIV proteinase specificity, marked differ-
ences were found in subsite specificity of these two types of
aromatic-Pro and hydrophobic-hydrophobic (not Pro) cleavage
sites; for example b-branched P2 residues are the best in type
II sites, but they are not optimal in type 1 sites due to steric
collision with P19 Pro (9, 14).
Subsites S1 and S19—Relative activities obtained with the
avian enzyme for the P1 substituted peptides were very similar
to those obtained with HIV-1 PR (see Table III) and EIAV PR
(11). None of the P1 modified peptides showed a relative activ-
ity higher than that obtained with the unsubstituted peptide
except that containing Phe instead of Tyr. Also, the kcat/Km
values for HIV-2 PR (10) and MuLV PR (38) suggested a very
similar preference for the P1 side chains, having Phe . Tyr .
Leu . Met for AMV, HIV-1, EIAV and MuLV PRs (for HIV-2,
Met substitution produced a higher kcat/Km value than substi-
tution with Leu). It is common in all cases that substitutions
having Gly, Ser, Asp, or Lys at P1 site gave nonhydrolyzable
substrates, whereas peptides with Ala, Val, Ile, or Trp gave
either noncleavable or very poor substrates. However, in the
NC/PR series Trp and Leu substitutions of the P1 Ser gave the
best values. The S1 and S3 subsites are overlapping (Fig. 6).
The P3 Gln of the MA/CA peptide restricts the available space
for P1 residue, whereas the P3 Ala in the NC/PR peptide does
not (Fig. 6). In naturally occurring cleavage sites for AMV,
HIV-1, HIV-2, and EIAV and also of other retroviral protein-
ases, hydrophobic amino acids predominate in P1 position (15).
Our results imply that the S1 binding site of all the studied
retroviral proteinases is very similar for the SP-211 substituted
peptides and in this sequence context the S1 sites do not con-
tribute substantially to the observed differences in specificity of
the PRs.
Based on molecular modeling, the S1 subsite is mainly hy-
drophobic, located deep inside the protein. Many of the residues
forming the S1 site of the HIV-1 and RSV PRs are conserved.
However, there are some nonconserved changes, including Val-
1049 (Thr-809), Arg-1059 (Pro-819), and Gly-1069 (Val-829). Arg-
1059 seems to contribute to both S1 and S3 subsites, whereas
Gly-1069 renders the RSV PR S1 pocket bigger than that of
HIV-1 PR (Fig. 6). It is an interesting feature of our substrate
series that the P1 Tyr side chain is predicted to occupy that
region, which is also a part of the S3 pocket. The S1 and S3
subsites seem to be overlapping much more than S4-S2, S2-S19,
S1-S29, and S19-S39 pockets. This could be a major factor in
sequence dependence of the results of specificity studies based
on different starting peptide sequences. Modeling also suggests
that depending on the P3 residue, OH of Tyr and the bulky Trp
side chain does not fit well into the AMV pocket, as was also
observed for HIV proteinases (9).
It is worth noting that the peptide containing Val at P1 was
hydrolyzed by AMV PR, but that containing Ile was not hydro-
lyzable. The peptides containing b-branched residues (Val and
Ile) at P1 of the MA/CA peptide were not hydrolyzable by HIV-1
FIG. 6. Interactions of P1 and P3 residues. Residues forming the S1 and S3 subsites of RSV (thin continuous lines) and HIV-1 (dashed lines)
proteinases are shown together with P3-P1 residues of two different substrates (in a ball-and-stick representation). The MA/CA substrate of HIV-1
is shown in thicker lines, and the NC/PR substrate of RSV with His at P3 is in thinner lines. The HIV-1 PR residues and the substrate residues
are from models based on the cystal structures of HIV-1 PR with peptide-like inhibitors.
TABLE V
Relative preference for Val over Leu substitutions of P2 Asn
of SP-211 as function of side chains in the proteinases
Proteinase Residues in equivalentpositions Relative preference
RSV Ile-44 Ile-64 6.6
EIAV Val-32 Ile-53 3.4
HIV-1 Val-32 Ile-47 2.8
HIV-2 Ile-32 Val-47 0.5
MuLV Val-39 Val-54 0.05a
a Taken from kcat/Km value (38). MuLV PR has many other changes in
the S2 pocket that might interfere with the role of the Val-39 and Val-54
in the enzyme-substrate interaction.
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and HIV-2 proteinases (9) and by EIAV PR (11). Similar results
were obtained for HIV-1 PR using another peptide series (40,
41). However, a small rate of hydrolysis was obtained with P1
Val and P1 Ile substituted SP-211 analogs with MuLV PR, and
this was attributed to the presence of Ala-57 instead of Ile in
HIV PRs. In the analogous position, AMV PR also contains
Ile-57, but the change of Gly-106 in place of Val-82 of HIV-1
may also provide a somewhat larger substrate binding pocket,
accepting b-branched residue.
Another common characteristic for the studied retroviral
proteinases is that changing the P19 proline in the type I
MA/CA peptide to any other tested amino acids (see Table III)
gave nonhydrolyzable or very poor substrates (9, 11), whereas
substitutions in Type II sequences provided good substrates
(21, 41). These results indicate that specificity at P19 position of
the retroviral PRs is also strongly dependent on the surround-
ing sequence.
Conclusion
Comparison of the specificity of the AMV PR to the HIV-1,
HIV-2, and EIAV proteinases using the type I MA/CA substrate
series, as well as comparing the AMV PR to HIV-1 PR speci-
ficity with the type II NC/PR substrate series suggests that
these PRs have many common features. All prefer hydrophobic
residues at the P1 position, although the optimal size of the
residue may depend on the residues forming S1 subsite and
may also be a function of the residue at P3. P19 Pro is unique in
the type I MA/CA peptide, because changing it to any other
tested amino acid prevented hydrolysis by the retroviral pro-
teinases (Table III and Refs. 9, 11, and 38). The size of the S2
and S29 subsites is restricted, and these are predicted to be the
smallest subsites in all cases, but the preference for P2 is
highly variable due to the different PR residues forming the S2
subsite and also depends on the P19 residue (9, 14), P1, and
perhaps the P4 residue. In the type I sequence context, the
preference for Asn by the HIV PRs is rather exceptional, be-
cause all of the other studied retroviral proteinases showed
much higher preference for small or medium sized hydrophobic
residues. Subsite S3 is more open than S2 and can accept a
variety of residues. Specificity in S3 is a function of the P1
residue; a large P1 side chain restricts the size of the P3 residue
that can be accommodated. Although S4 is close to the surface,
it shows a preference for hydrophobic residues except for HIV
PRs, although the size of the preferred residue is a function of
P2. Our results suggest that the specificity of retroviral pro-
teinases is very complex and strongly depends on the context of
the substrate sequence. The preference at a given position may
depend not only on the complementarity of residues at the
same side of the b sheet (like P3 and P1, P2 and P19) but also
on those at the opposite side. However, modeling in many cases
could give an explanation for the sequence context dependence
and is a promising tool to “decode” the specificity of the retro-
viral proteinases. The strong sequence context dependence
should be taken into account in the design of proteinase inhib-
itors, because developing resistance is one of the most serious
problems in treatment of AIDS. A mutation in a substrate
binding subsite of the PR indirectly could influence the speci-
ficity of the other binding sites. Conversely, changing the li-
gand at those other affected positions could complement the
changes and regain the high potency of the enzyme-ligand
interaction.
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